Aldon Fernandes PhD.’s Post

Another milestone not only for solid tumors and #allogeneic #NK #celltherapy, but also for cryopreserved starting material! The #cryopreservation process allows to maintain significant cellular cytotoxicity, and potentially making hundreds of thousands of #NKcell doses from a single donor. Learn how CPC Services can help your #clinicaltrial patient sample processing and cryopreservation and storage of starting material. www.cpcservices.com https://lnkd.in/eSPurzXs #immunotherapy #cancerresearch #clinicalresearch

Tumor infiltrating lymphocytes: complex science, but maybe even more complex launch. At 515K$ per treatment, Iovance will face challenges. TIL therapy originated from research at the National Institutes of Health in the 1980s. It took decades to fine-tune, and Iovance had to overcome multiple regulatory delays bringing the therapy, formerly known as lifileucel, to market. Its clearance is the “culmination of scientific and clinical research efforts,” https://lnkd.in/ebbBwVr3

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial https://lnkd.in/ep2CdfjZ

💎💎💎Whatsapp!! 💎💎💎CD5 deletion enhances the antitumor activity of adoptive T cell therapies. The currently available #chimeric #antigen #receptor ( #CAR) #T #cell #therapies have had limited efficacy for a wide range of #solid #cancers and #hematological #malignancies, due in part to CAR T cell #dysfunction. The #scavenger #receptor CD5 is associated with the T cell receptor ( #TCR) and inhibits T cell function. Patel et al. show that #genetic_deletion of #CD5 in #CAR and #TCR T cells enhances expansion, persistence, and #cytotoxicity and is #effective in preclinical solid tumor and hematological malignancy models. These results suggest that CD5 may be a critical negative regulator of CAR T cells that can be therapeutically targeted. ➡ 💎 You can find more pieces of work by clicking here. https://lnkd.in/eSG67K5G https://lnkd.in/dB3s88ei #chimeric #antigen #receptor #CAR #T #cell #therapies

#Bispecific #Ivonescimab #NSCLC #PD-1 #VEGF Akeso ---Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in Randomized Phase III Clinical Trial in NSCLC --Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Trial Conducted by Akeso --PFS Improvement Was Observed Broadly in Patients Across Subgroups, including PD-L1 Low and PD-L1 High Expressing Tumors, Squamous and Non-Squamous Histologies --- Ivonescimab is a bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule https://lnkd.in/grurkhXF

Remember the catchphrase from the #Ginsu knives commercial from the ‘80s: “But wait! There’s more!”? The pharmaceutical equivalent of Ginsu knives is the EpicentRx lead therapy, RRx-001 (nibrozetone), which is potentially active in a whole host of indications from cancer to endometriosis, oral mucositis, myocardial infarction, stroke, pulmonary hypertension, and neurodegenerative diseases. But wait! There’s more - so much more to read in this blog post here: https://bit.ly/45yklCS.

New study!🏹 A high-content screen of FDA approved drugs to enhance #CART cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation ------------------------ CAR T cell therapy is a promising approach to improve outcomes and decrease toxicities for patients with cancer. While extraordinary success has been achieved using CAR T cells to treat patients with CD19-positive malignancies, multiple obstacles have so far limited the benefit of CAR T cell therapy for patients with solid tumors. Novel manufacturing and engineering approaches show great promise to enhance CAR T cell function against solid tumors. However, similar to single agent chemotherapy approaches, CAR T cell monotherapy may be unable to achieve high cure rates for patients with difficult to treat solid tumors. Here Christopher DeRenzo, Ha Won Lee et al. developed a novel, confocal microscopy based, high-content screen to evaluate 1114 FDA approved drugs for the potential to increase expression of the solid tumor antigen B7-H3 on the surface of osteosarcoma cells. The Authors demonstrates a novel high-content and high-throughput screen can identify drugs to enhance CAR T cell activity. For free⤵️ https://lnkd.in/dSayed_b #Tcell #Osteosarcoma IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

This recent review of the latest clinical developments in GBM (immunotherapy and targeted approaches) offers interesting perspectives for early drug discovery and development: 🎯 Improve drug delivery system 🤝 consider combos, including immune combination therapies and better explore interaction between SoC and your lead before clinical trials. 💻 huge need for big data technologies and intelligent experimental platforms to overcome tumor heterogeneity (inter patient, intra-tumor and over recurrence) as well as the complex role of tumor micro-environment https://lnkd.in/e2XpTHW6

#News: Adaptimmune has won accelerated FDA approval for #Tecelra #(afami-cel), a treatment for #metastatic or #unresectable #synovialsarcoma. Tecelra’s approval comes with several firsts. It’s the first #engineered #celltherapy for a #solidtumor, the first #TCRTtherapy to enter the market, and the first new treatment in the indication in more than a decade. It also is the initial approval for the 16-year-old company, which has attracted and lost partnerships with several pharma giants—including GSK, Astellas and most recently Roche—who were drawn to the potential of Adaptimmune’s unique engineered T-cell receptor (TCR) platform. It enables the engineering of T-cells to target and destroy many types of solid tumor cancers. As the first engineered T-cell therapy for solid tumors, Tecelra marks a significant milestone, not only for the company but also for the advancement of #celltherapy. “It’s the first product where we use a #lentiviralvector to insert our engineered #Tcellreceptor into the cell,” John Lunger, Adaptimmune’s chief patient supply officer, explained in an interview. Iovance Biotherapeutics, Inc.’s #Amtagvi (#lifileucel), which was approved by the FDA in February for #melanoma, was the first T-cell treatment for solid tumors. The difference with Tecelra is that it is #engineered. Read more from Fierce Pharma 👇🏼

Cellectar recently announced topline data for Iopofosine, their potential first-in-class, targeted radiotherapy candidate for the treatment of relapsed/refractory Waldenstrom’s macroglobulinemia (WM). Results were promising with its primary endpoint met with a major response rate (MRR) of 61% (95% confidence interval [44.50%, 75.80%, two-sided p value < 0.0001]). The overall response rate (ORR) in evaluable patients was 75.6%, and 100% of patients experienced disease control. https://lnkd.in/eiPgcXqn #oncology #clinicaltrials #biotech #radiotherapy